Improving Access To Affordable Prescription Drugs Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Mar 29, 2017)
This bill amends provisions of various laws relating to prescription-drug pricing and affordability. Specifically, the bill:
- expands reporting requirements for drug manufacturers and establishes corresponding civil penalties for noncompliance;
- adds reporting requirements for certain nonprofit patient-assistance programs;
- requires the Government Accountability Office (GAO) to report to Congress on the impact of patient-assistance programs on prescription-drug pricing and expenditures;
- requires the Centers for Medicare & Medicaid Services (CMS) to negotiate prices for certain prescription drugs under the Medicare program;
- requires the GAO to report to Congress on such negotiations conducted by the CMS;
- requires the Centers for Medicare and Medicaid Innovation within the CMS to test specified models for negotiating drug prices;
- establishes reporting requirements, and corresponding civil penalties for noncompliance, for pharmaceutical companies with respect to spikes in prescription-drug prices;
- establishes an excise tax on prescription drugs subject to price spikes;
- lessens prescription-drug cost-sharing requirements under qualified health plans, group health plans, and the Medicare program;
- modifies provisions related to the importation of prescription drugs;
- requires drug manufacturers to provide drug rebates for drugs dispensed to certain low-income individuals under the Medicare program;
- establishes a prize fund for new and more effective treatments of bacterial infections;
- establishes a Center for Clinical Research within the National Institutes of Health;
- modifies provisions related to drug exclusivity;
- allows the Federal Trade Commission to initiate enforcement proceedings against parties to an agreement resolving or settling a patent-infringement claim in connection with the sale of a drug product;
- requires the Food and Drug Administration to establish a database of generic drugs; and
- modifies other provisions related to generic drugs, prescription-drug advertising, and product hopping.
What just happenedApr 5, 2017
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseMar 29, 2017
- Apr 5, 2017Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Mar 31, 2017Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Mar 29, 2017IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Judiciary Committee - Mar 29, 2017IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Mar 29, 2017IntroReferralH11100-A
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Mar 29, 2017IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Mar 29, 2017IntroReferralIntro-H
Introduced in House
- Mar 29, 2017IntroReferral1000
Introduced in House